Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01784757 | Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer(ARAFOR) | completed | Phase 1 | 30 | Orion Corporation, Orion PharmaINDUSTRY | 1 | Mar 17, 2021 | clinicaltrials |
| NCT03213964 | Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int | completed | Phase 1 | 10 | Masonic Cancer Center, University of MinnesotaOTHER | 1 |
| Mar 12, 2021 |
| clinicaltrials |
| NCT01322802 | Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer | completed | Phase 1 | 25 | University of WashingtonOTHER | 1 | Feb 25, 2021 | clinicaltrials |
| NCT01989546 | Pilot Trial of BMN 673, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Deleterious BRCA Mutations | completed | Phase 1 / Phase 2 | 9 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2021 | clinicaltrials |
| NCT02172911 | A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer | completed | Phase 1 / Phase 2 | 10 | Inovio PharmaceuticalsINDUSTRY | 1 | Feb 21, 2021 | clinicaltrials |
| NCT01623349 | Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer | completed | Phase 1 | 118 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2021 | clinicaltrials |
| NCT02411786 | A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF | completed | Phase 1 | 40 | University of Wisconsin, MadisonOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT00003450 | Gene Therapy in Treating Patients With Advanced Recurrent or Persistent Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | — | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 2, 2021 | clinicaltrials |
| NCT02004418 | A Study for Patients With Prostate Cancer to See Whether Delivering an Extra Dose of Radiation to Parts of the Body With More Cancer is Better Than Standard Treatment in Which the Same Dose of Radiation is Given Throughout the Prostate Gland(PET PRO) | completed | Phase 1 / Phase 2 | 21 | AHS Cancer Control AlbertaOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02179515 | Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM) | completed | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03697226 | Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection. | completed | Phase 1 | 8 | Antiva BiosciencesINDUSTRY | 1 | Jan 13, 2021 | clinicaltrials |
| NCT02730975 | Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer(ABIFOOD01) | completed | Phase 1 | 42 | Fundación Pública Andaluza para la gestión de la Investigación en SevillaOTHER | 1 | Jan 11, 2021 | clinicaltrials |
| NCT01646684 | Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Pasireotide LAR in Patients With Castration Resistant Prostate Cancer | completed | Phase 1 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2020 | clinicaltrials |
| NCT00663832 | A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer | completed | Phase 1 | 44 | Novartis PharmaceuticalsINDUSTRY | 2 | Dec 19, 2020 | clinicaltrials |
| NCT01338831 | Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer | completed | Phase 1 | 73 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT01634061 | Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients | completed | Phase 1 | 43 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 9, 2020 | clinicaltrials |
| NCT01068483 | Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients | completed | Phase 1 | 107 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 8, 2020 | clinicaltrials |
| NCT02883166 | Improving Bio-availability of the Expensive Oral Oncolytic Drug Abiraterone by Food Intake(SNACK) | completed | Phase 1 | 14 | Radboud University Medical CenterOTHER | 1 | Dec 7, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT00765973 | Topotecan Liposomes Injection for Small Cell Lung Cancer (SCLC), Ovarian Cancer and Other Advanced Solid Tumors | completed | Phase 1 | 14 | Spectrum Pharmaceuticals, IncINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03704467 | Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer | completed | Phase 1 | 3 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 3 | Nov 13, 2020 | clinicaltrials |
| NCT03480750 | Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer(Trientine) | completed | Phase 1 / Phase 2 | 18 | National Cheng-Kung University HospitalOTHER | 0 | Nov 10, 2020 | clinicaltrials |
| NCT03774056 | A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients. | completed | Phase 1 | 43 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03778047 | A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch | completed | Phase 1 | 10 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03538028 | A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies | completed | Phase 1 | 22 | Incyte Biosciences International SàrlINDUSTRY | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03183544 | Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit(PSMA) | completed | Phase 1 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT03101280 | A Combination Study of Rucaparib and Atezolizumab in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer | completed | Phase 1 | 29 | Hoffmann-La RocheINDUSTRY | 4 | Oct 22, 2020 | clinicaltrials |
| NCT01935973 | Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 14, 2020 | clinicaltrials |
| NCT02472275 | PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer | completed | Phase 1 | 8 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT02693860 | Neoadjuvant J591 Treatment for Prostate Cancer | completed | Phase 1 | 8 | Weill Medical College of Cornell UniversityOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT02429466 | Study of the Hypomethylating Drug Guadecitabine (SGI-110) Plus Cisplatin in Relapsed Refractory Germ Cell Tumors | completed | Phase 1 | 14 | Nasser HannaOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT01649336 | A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | completed | Phase 1 | 36 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Sep 14, 2020 | clinicaltrials |
| NCT03384316 | Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer | completed | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00959959 | ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer(ARMOR1) | completed | Phase 1 | 49 | LTN PHARMACEUTICALS, INC.INDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT01931046 | Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer | completed | Phase 1 / Phase 2 | 28 | Momotaro-Gene Inc.INDUSTRY | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03030287 | A Phase 1b Study of OMP-305B83 Plus Paclitaxel in Subjects With Ovarian, Peritoneal or Fallopian Tube Cancer | completed | Phase 1 | 44 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 3, 2020 | clinicaltrials |
| NCT01711515 | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2020 | clinicaltrials |
| NCT02121990 | Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02658214 | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 2 | Aug 20, 2020 | clinicaltrials |
| NCT03158935 | The ACTIVATE (Adoptive Cell Therapy InVigorated to Augment Tumor Eradication) Trial(ACTIVATE) | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Aug 14, 2020 | clinicaltrials |
| NCT02092363 | Dose Escalation Study of OMP-54F28 in Combination With Paclitaxel and Carboplatin in Patients With Recurrent Platinum-Sensitive Ovarian Cancer | completed | Phase 1 | 37 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT03430518 | Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer | completed | Phase 1 | 9 | Amy TierstenOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00064129 | Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancer | completed | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 30, 2020 | clinicaltrials |
| NCT02092948 | Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer | completed | Phase 1 | 8 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT03362359 | Ga-68-PSMA-11 in High-risk Prostate Cancer | completed | Phase 1 / Phase 2 | 173 | German Cancer Research CenterOTHER | 2 | Jul 27, 2020 | clinicaltrials |
| NCT02747342 | A Phase 1 Trial of SHR3680 With or Without SHR3162 in Prostate Cancer | completed | Phase 1 | 33 | Atridia Pty Ltd.INDUSTRY | 1 | Jul 21, 2020 | clinicaltrials |
| NCT02924766 | A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE) | completed | Phase 1 | 34 | Janssen Research & Development, LLCINDUSTRY | 2 | Jul 20, 2020 | clinicaltrials |
| NCT01263327 | Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine | completed | Phase 1 | 38 | Xiamen UniversityOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT03199872 | RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours | completed | Phase 1 / Phase 2 | 22 | RhoVac APSINDUSTRY | 1 | Jun 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 17, 2021source: clinicaltrials